IMPAKT 2017: Liquid Biopsy in Breast Cancer Practice

Speaker: Michail Ignatiadis

Michail Ignatiadis explains that breast tumours evolve over time and liquid biopsy can help to follow circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA). 

Meta-analysis have already confirmed that CTCs have a prognostic value. However, some very promising data from ongoing trials show that CT DNA may be useful to track genomic aberations in plasma and guide the treatment selection.

In the future, liquid biopsy may be used to monitor tumour evolution to adapt treatment for precision medicine, and improve patient selection. Liquid biopsy can also accelerate drug development in early breast cancer by helping to identify the high risk patients eligible for new drugs and by improving residual disease assessment.

Discussion Points

  • Which tools are at disposal for interrogating a liquid biopsy?
  • Where do we stand with liquid biopsy application in clinical care of breast cancer
  • Future outlook in liquid biopsy: Breast cancer and beyond